Cancer Causes Control by Wu, Anna H. et al.
The California Breast Cancer Survivorship Consortium (CBCSC): 
Prognostic factors associated with racial/ethnic differences in 
breast cancer survival
Anna H. Wu,
University of Southern California, Los Angeles, CA
Scarlett Lin Gomez,
Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, 
Stanford, CA
Cheryl Vigen,
University of Southern California, Los Angeles, CA
Marilyn L. Kwan,
Division of Research, Kaiser Permanente Northern California, Oakland, CA
Theresa H.M. Keegan,
Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, 
Stanford, CA
Yani Lu,
City of Hope, Duarte, CA
Salma Shariff-Marco,
Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, 
Stanford, CA
Kristine R. Monroe,
University of Southern California, Los Angeles, CA
Allison W. Kurian,
Stanford University School of Medicine, Stanford, CA
Iona Cheng,
Cancer Prevention Institute of California, Fremont, CA
Bette J. Caan,
Division of Research, Kaiser Permanente Northern California, Oakland, CA
Valerie S. Lee,
Division of Research, Kaiser Permanente Northern California, Oakland, CA
To whom correspondence should be addressed: Anna H. Wu, Department of Preventive Medicine, University of Southern California 
Keck School of Medicine, 1441 Eastlake Avenue, Rm 4443, Los Angeles CA 90089 (annawu@usc.edu), phone: 323 865-0484; fax: 
323-865-0139. 
Conflict of interest: None
HHS Public Access
Author manuscript
Cancer Causes Control. Author manuscript; available in PMC 2014 June 05.
Published in final edited form as:














Division of Research, Kaiser Permanente Northern California, Oakland, CA
Jane Sullivan-Halley,
City of Hope, Duarte, CA
Brian E. Henderson,
University of Southern California, Los Angeles, CA
Leslie Bernstein,
City of Hope, Duarte, CA
Esther M. John, and
Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, 
Stanford, CA
Richard Sposto
University of Southern California, Los Angeles, CA
Abstract
Racial/ethnic disparities in mortality among US breast cancer patients are well-documented. Our 
knowledge of the contribution of lifestyle factors to disease prognosis is based primarily on non-
Latina Whites and is limited for Latina, African American and Asian American women. To 
address this knowledge gap, the California Breast Cancer Survivorship Consortium (CBCSC) 
harmonized and pooled interview information (e.g., demographics, family history of breast cancer, 
parity, smoking, alcohol consumption) from six California-based breast cancer studies and 
assembled corresponding cancer registry data (clinical characteristics, mortality), resulting in 
12,210 patients (6,501 non-Latina Whites, 2,060 African Americans, 2,032 Latinas, 1,505 Asian 
Americans, 112 other race/ethnicity) diagnosed with primary invasive breast cancer between 1993 
and 2007. In total, 3,047 deaths (1,570 breast cancer-specific) were observed with a mean (SD) 
follow-up of 8.3 (3.5) years. Cox-proportional hazards regression models were fit to data to 
estimate hazards ratios (HR) and 95% confidence intervals (CI) for overall and breast cancer-
specific mortality. Compared with non-Latina Whites, the HR of breast cancer-specific mortality 
was 1.13 (95% CI, 0.97-1.33) for African Americans, 0.84 (95% CI, 0.70-1.00) for Latinas, and 
0.60 (95% CI, 0.37-0.97) for Asian Americans after adjustment for age, tumor characteristics, and 
select lifestyle factors. The CBCSC represents a large and racially/ethnically diverse cohort of 
breast cancer patients from California. This cohort will enable analyses to jointly consider a 
variety of clinical, lifestyle, and contextual factors in attempting to explain the long-standing 
disparities in breast cancer outcomes.
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Differences in breast cancer mortality rates by race and ethnicity in the United States (US) 
have long been recognized. Mortality rates were similar for African Americans and non-
Latina Whites until the late 1970s; in the early 1980s, these rates began to diverge with 
higher mortality in African Americans and have continued despite the lower breast cancer 
incidence in African Americans compared to non-Latina Whites (1-4). Based on 
Surveillance, Epidemiology and End Results (SEER) Registry data between 1993 and 1998, 
risk of death after breast cancer diagnosis was two-fold higher in African Americans, 30% 
higher in Latinas, and 10% lower in Asian Americans than in non-Latina Whites (5). The 
relative survival disparities by race/ethnicity have persisted in studies that used SEER data 
between 2000 and 2006 (6).
Racial/ethnic differences in survival after a breast cancer diagnosis can be attributed to 
multiple factors. They include differences in stage at diagnosis, which may be related to 
access to and utilization of mammography screening and health care, differences in the 
quality of care after diagnosis, factors that are related to socioeconomic status (SES) of 
patients and neighborhoods, and other neighborhood and medical institutional factors (7). 
Differences in tumor characteristics and aggressiveness, as well as treatment response, may 
also be related to racial/ethnic differences in genetic susceptibility and tumor biology. 
However, adjustment for stage at diagnosis, other tumor characteristics, first course 
treatment, and area-based SES have not completely explained the survival differences 
between African Americans and non-Latina Whites (6).
Lifestyle factors, including large body size (8-13), lack of regular exercise (14-16), a history 
of comorbid conditions (17-19), and low community-level SES (20) have also been 
independently and positively associated with the risk of death after breast cancer diagnosis. 
Given that these factors differ by race/ethnicity (17, 21-24), they may contribute to the long-
standing racial/ethnic disparities in breast cancer survival. A common shortcoming of many 
previous studies is the inability to investigate multiple, interrelated factors that may exert 
independent, as well as combined, effects on survival, either due to limited availability of 
data as in cancer registry-based studies or small numbers of racial/ethnic minority 
populations in observational studies. Thus, much of our current knowledge of these 
prognostic factors is based on studies conducted predominantly in non-Latina White breast 
cancer patients, with some information available for African Americans (17, 25, 26), and 
sparse data on Latinas and Asian Americans (26).
The California Breast Cancer Survivorship Consortium (CBCSC) was established in 2011 as 
a collaborative effort that leverages data collected by six California-based studies of over 
12,000 breast cancer patients. The inclusion of breast cancer cases from four racial/ethnic 
groups (African Americans, Asian Americans, Latinas, and non-Latina Whites) offers a 
unique opportunity to study the individual, clinical, and contextual factors as potential 
determinants of the observed survival disparities across racial/ethnic groups. Using 
harmonized questionnaire data on a variety of prognostic factors, enriched with commonly-
derived clinical and follow-up information from the population-based, statewide California 
Cancer Registry (CCR), the CBCSC addresses many of the limitations of previous studies 
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by having adequate sample size and information on individual lifestyle prognostic factors. In 
this paper, we describe the methods used to assemble the CBCSC and report on the risks of 
overall and breast cancer-specific mortality in African Americans, Latinas and Asian 
Americans relative to non-Latina Whites in this pooled cohort.
Materials and Methods
Structure and Composition of CBCSC
The CBCSC is comprised of six epidemiologic studies of breast cancer etiology and/or 
prognosis that were initiated in the 1990's and early 2000's. Details of these six studies 
(study design, age and racial/ethnic composition, study location, data collection methods) 
are described in Table 1. These six studies initially yielded 12,787 female breast cancer 
cases (6,695 non-Latina Whites, 2,223 African Americans, 2,120 Latinas, 1,636 Asian 
Americans, 113 other race/ethnicity). Individual study investigators received Institutional 
Review Board (IRB) approval from their respective institution(s) to participate in this 
collaboration, and IRB approval was also obtained from the State of California Committee 
for the Protection of Human Subjects for the use of CCR data.
During a one-year pilot study, prognostic factors were identified that potentially could be 
harmonized across the CBCSC studies, given similar measurement across studies, and 
considerable variation in their distribution across racial/ethnic groups; these factors were 
body size, physical activity, and co-morbidities. Furthermore, linkage with geocoded patient 
records allowed us to identify institutional and neighborhood social and built environment 
factors that also showed racial/ethnic variation (24, 27). The study objectives and activities 
of the CBCSC were organized into four individual projects, each focused on a specific set of 
potential prognostic factors: Project 1: contextual factors (institutional and social and built 
environment, including distance to health care facility, walkability); Project 2: physical 
activity; Project 3: body size; and Project 4: co-morbidities. The three case-control studies 
contributed data to all four projects, whereas the cohort studies contributed data to a subset 
of the projects (Figure 1). For each project, working groups are organized that utilize 
research expertise among CBCSC investigators and includes representatives from all 
participating centers.
The systematic assembly of data for the four projects was facilitated by the Cancer Registry 
Data Core (CRDC) and the Questionnaire Data Core (QDC), and a common data dictionary 
and analytic plan were developed. The CBCSC received feedback from a team of external 
advisors with expertise in oncology, social sciences, health disparities, and patient advocacy.
Cancer Registry Data Core (CRDC)
The role of the CRDC was to centralize and streamline the ascertainment of cancer registry 
variables from the CCR for the four projects. The CCR is a state-mandated population-based 
cancer registry that is part of the SEER program. Through its regional registries, the CCR 
routinely collects patient data from medical records on age at diagnosis, sex, race/ethnicity, 
marital status, birthplace, and tumor characteristics (American Joint Committee on Cancer 
(AJCC) stage, tumor size, grade, nodal involvement, histology, estrogen receptor (ER) and 
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progesterone receptor (PR) status, laterality, HER2 (although missing for most cases prior to 
2004, and thus not further considered)), first course of treatment (extent of surgical 
resection, chemotherapy, radiation), and vital status (including cause of death for the 
deceased) through hospital follow-up and linkages to vital statistics, death records, and other 
databases. Given that multiple tumors of an individual are captured, data on cancer(s) prior 
to and subsequent to the qualifying tumors for CBCSC eligibility are also available insofar 
as the women remain a resident of California.
Each participating study provided either unique CCR identification numbers or personal 
patient identifiers to enable linkage to the CCR database. The CRDC then consolidated and 
created a dataset of clinical (tumor characteristics and treatment data), survival, and census 
block group SES variables. Missing clinical data from the CCR, such as chemotherapy, were 
not supplemented with data available from contributing study sources, given that these data 
were not collected systematically by all studies. Vital status as of December 31, 2009, the 
end of follow-up period of this study, was used to ensure, to the extent possible, that all 
cases in the pooled analysis had comparable opportunity for follow-up. Breast cancer-
specific deaths were derived from the underlying cause of death on the death certificate 
based on ICD-9 (9174) or ICD-10 (C50) codes. Patients' addresses at diagnosis are routinely 
geocoded by the CCR to coordinates (latitude, longitude). Neighborhood SES at the block 
group level was assigned to cases with at least a zip code+4 digit postal extension, using a 
previously developed index that incorporates US census data on education, occupation, 
unemployment, household income, poverty, rent, and house values (28). Cases diagnosed 
prior to 1996 were assigned to the SES measure developed with the 1990 census data, and 
those diagnosed in 1996 or later were assigned to the measure using 2000 census data.
Questionnaire Data Core (QDC)
The role of the QDC was to harmonize a select set of demographic and lifestyle factors 
considered to be relevant covariates for adjustment in all of the project analyses. We 
considered in our base model reproductive variables including parity, number of births and 
timing of first birth, alcohol consumption, and smoking as these factors have been found to 
influence mortality in breast cancer patients in some studies and may also influence 
mortality via hormonally mediated pathways (29-34). Each of the six studies provided 
specific questionnaire variables that were then harmonized and merged into a common 
dataset. This pooled dataset included basic demographic variables (date of birth, race/
ethnicity, education, birthplace, age at migration to the US if foreign-born, language of 
interview), and the major suggested breast cancer risk and prognostic factors, including 
pregnancies (number and outcome of pregnancies, ages at first and last birth), menopause 
(type of menopause, age at menopause), family history of breast cancer (number of affected 
first-degree relatives, age at diagnosis of the affected relatives), smoking pattern (never/
former/ current, number of cigarettes smoked per day) and alcohol consumption before 
breast cancer diagnosis.
For some variables (race/ethnicity, birthplace, education, parity, age at first birth, time since 
last birth, family history of breast cancer, age at diagnosis of affected relatives), the 
questionnaire response categories were similar across the studies although the definitions 
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were not always identical. For example, although all studies collected information on family 
history of breast cancer in first-degree female relatives, several studies asked about cancer 
history in full siblings (LACE, CTS, MEC), whereas two studies collected data separately 
for both full- and half-sisters (AABCS, CARE), and this information was not specified in 
another study (SFBCS). We left these data as they were originally coded, given that it is not 
possible to re-define the categories used by the contributing studies. The differences in 
classification caused by these inconsistencies are likely to be minimal. Other variables such 
as alcohol consumption and smoking (cigarettes per day among former and current smokers) 
were collected as continuous variables in some studies (AABCS, CARE, SFBCS, LACE) 
but as categorical variables in other studies (CTS, MEC); the midpoint of a category was 
assigned for the latter group. The questions that were used to assess menopausal status 
varied across the six studies. However, because each of the studies had carefully developed 
its own algorithm to determine menopausal status, we relied on each study's original 
classification of menopausal status.
Pooling Process
Of the initial 12,787 breast cancer case participants from the six studies submitted to the 
CRDC, 577 cases were excluded for various reasons (Figure 1, Study Exclusions). For the 
492 cases who participated in more than one study, resulting in 506 duplicate records, we 
applied an inclusion rule to use data from the case-control studies first and then from the 
cohort studies in the order of LACE, CTS, and MEC. The final analytic dataset included 
12,210 breast cancer cases (6,501 non-Latina Whites, 2,060 African Americans, 2,032 
Latinas, 1,505 Asians Americans, 112 other race/ethnicity) (Figure 1). For a small group of 
cases (n=126) with multiple breast tumors diagnosed on the same day, we designated the 
study-qualifying tumor based on a combination of stage, grade, and histology, and 
considered the worst prognosis tumor as the qualifying tumor.
We evaluated the representativeness of the 12,210 breast cancer cases included in the 
CBCSC to all breast cancers identified by the CCR (excluding in situ cases and those with 
<30 days of follow-up) diagnosed in women between 1993 and 2007 in California. The CCR 
group included 208,542 non-Latina Whites, 17,099 African Americans, 38,459 Latinas, and 
24,958 Asian Americans. We compared key tumor characteristics, with the goal of 
identifying any specific patterns of differences in distribution by race/ethnicity.
Common Analytic Plan
A common analytic approach was developed to facilitate the evaluation of the degree to 
which the residual race/ethnicity differences in overall and breast cancer-specific mortality 
could be explained by racial/ethnic differences in social and built environment and 
neighborhood factors, physical activity, body size, and co-morbidity variables after 
controlling for important tumor and lifestyle factors. We first developed a main effects 
stratified Cox regression model to estimate hazard ratios (HR) and associated 95% 
confidence intervals (CIs) by reverse stepwise selection. The starting model included ‘study’ 
as a stratification factor and all of the tumor characteristic and lifestyle variables (available 
in the CRDC and QDC). Age at diagnosis was included as a continuous variable on both the 
natural scale and the log10 scale in order to appropriately account for the ordered effect of 
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age and allow for non-linearity in its effect in the Cox model. Two time scales, time from 
diagnosis and attained age (35, 36) were investigated in the development of the final 
baseline models for overall and breast cancer-specific mortality. All variables, except for 
age at diagnosis were subject to removal using backward stepwise regression. The order of 
removal was determined by the more significant (between the two time scales) of the Cox 
partial likelihood ratio test for that variable, and removal continued until all remaining 
variables had a likelihood ratio p-value of <0.20. No interactions were included in the 
model. Women in the case-control studies (AABCS, CARE, SFBCS) and the prospective 
survivor cohort (LACE) survived after diagnosis until the time of data collection; thus their 
follow-up was left censored since women who died or were lost to follow-up before data 
collection by the parent study were not included in this study. The mean (SD) years from 
diagnosis to data collection were 1.6 (0.8) for AABCS, 0.4 (0.3) for CARE, 1.4 (0.6) for 
SFBCS, and 1.8 (0.5) for LACE. Women in these four studies were admitted to the risk set 
at the time of data collection rather than at the time of diagnosis. Women in the prospective 
population cohorts (CTS, MEC) were included in the pooled analysis if their breast cancer 
diagnosis occurred during the study follow-up period. The mean (SD) number of years 
between data collection and cancer diagnosis was 6.9 (4.0) for MEC and 5.0 (2.8) for CTS. 
The percentages of women diagnosed within 1 year, 1-<2 years, 2 to <5 years, and 5 or more 
years after questionnaire completion were 8.1%, 6.4%, 21.0%, and 64.5%, respectively, for 
the MEC. The corresponding figures were 9.3%, 9.8%, 31.2%, and 49.7% in the CTS. 
Women were followed until death; for breast cancer-specific death, we censored women 
who died of other causes on their dates of death.
The HRs for overall and breast cancer-specific mortality in African Americans, Latinas, and 
Asian Americans relative to non-Latina Whites determined from the fully adjusted baseline 
models were compared to the corresponding HR estimates obtained in models adjusted for a 
limited number of clinical variables (age at diagnosis, race/ethnicity, registry region, AJCC 
stage, ER/PR status, surgery type, radiation therapy) and excluded lifestyle factors including 
parity, alcohol consumption, and smoking history (referred to as “Limited Model”). The 
limited models were used in previous SEER-based studies (5, 6, 37). To evaluate the 
potential confounding by study and race/ethnicity (e.g., AABCS contributed data only to the 
analysis on Asian Americans and over 70% of Latina data were from SFBCS), we repeated 
the analysis excluding ‘study’ as a stratification factor. We also compared the HR results in 
CBCSC women to all breast cancer patients in the CCR.
Results
Characteristics of the breast cancer cases included in the pooled analysis (n=12,210) are 
shown in Tables 2 and 3. Large proportions of Asian Americans (66.6%) and Latinas 
(43.5%) were foreign-born. Low neighborhood SES was most common among African 
Americans (27.6%), followed by Latinas (13.3%), Asian Americans (9.3%), and non-Latina 
Whites (3.2%). Similarly, the frequency of tumor characteristics associated with worse 
survival (i.e., Stage III/IV, grade III/IV, nodal involvement, tumor size ≥5 cm, and ER 
negative/PR negative) tended to be highest in African Americans, followed by Latinas, 
Asian Americans and non-Latina Whites. These distributions of tumor characteristics 
differed significantly between non-Latina Whites and each of the other three racial/ethnic 
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groups. With the exception of tumor histology, most of the other tumor characteristics also 
differed significantly between African Americans, Latinas, and Asian Americans (Table 2).
Most of the lifestyle factors also differed significantly between the four racial/ethnic groups. 
Low education (some high school or less) and ≥4 births were most frequent in Latinas 
(37.1% and 33.0%, respectively), and first birth at age <20 years (44.7%) and a history of 
smoking (53.1%) in African Americans; whereas a positive family history of breast cancer 
(19.4%) and a history of regular alcohol use (65.6%) was most frequent in non-Latina 
Whites (Table 3).
Table 4 shows characteristics of the breast cancer cases included in CBCSC compared to all 
invasive breast cancers diagnosed in California identified by the CCR during 1993-2007. In 
general, breast cancer cases in CBCSC had proportionally fewer stage III/IV cancers than 
those in the CCR; this pattern was consistently observed across all four racial/ethnic groups. 
The prevalence of ER negative tumors was also consistently lower in CBCSC breast cancer 
cases than in the CCR. However, the prevalence of poorly differentiated tumors (Grade III 
or IV) was comparable in CBCSC and the CCR. Differences in neighborhood SES also 
existed between breast cancer cases in CBCSC and in the CCR: a higher percentage of non-
Latina Whites and Latinas in CBCSC lived in the highest SES neighborhoods (40.9% and 
21.7%, respectively) compared to those in the CCR (31.5% and 11.4%, respectively). The 
percentage of African Americans living in the highest SES neighborhoods was comparable 
in CBCSC (8.9%) and the CCR (8.6%), but there was some underrepresentation of high SES 
Asian Americans in CBCSC (27.9%) compared with the CCR (31.0%).
Separate baseline models for overall and breast cancer-specific mortality were built using 
time from diagnosis and attained age time scales. Tumor characteristics from Table 2 
including stage, grade, nodal involvement, tumor size, ER/PR status, chemotherapy, prior 
tumor, and surgery type remained statistically significant in the final model (Table 5). 
Demographic factors (race/ethnicity, education, neighborhood SES, marital status), 
reproductive/lifestyle factors (age at first birth, alcohol consumption, smoking) and other 
factors (nativity, years of diagnosis, and region of residency) remained statistically 
significant in the final model for overall mortality using attained age time scales (Table 5). 
Results using time from diagnosis were very similar (data not shown) though the use of 
attained age appeared to provide a slightly better model fit for both overall and breast 
cancer-specific mortality. Most of the HRs were similar for overall and breast cancer-
specific mortality, but there were somewhat stronger effects of stage, grade, nodal 
involvement, and tumor size on breast cancer-specific mortality (Table 5).
A total of 3,047 deaths were observed after a mean (SD) follow-up of 8.3 (3.5) years. 
Compared with non-Latina Whites, the HR (95% CI) for overall mortality was 1.02 
(0.91-1.15) for African Americans, 0.75 (0.65-0.87) for Latinas, and 0.76 (0.57-1.01) for 
Asian Americans in our fully adjusted baseline model that included all significant clinical 
characteristics and lifestyle factors with stratification by study. Larger racial/ethnic 
differences were observed when we restricted the analysis to the 1,570 breast cancer-specific 
deaths. Compared with non-Latina Whites, the HR (95% CI) was 1.13 (0.97-1.33) for 
African Americans, 0.84 (0.70-1.00) for Latinas, and 0.60 (0.37-0.97) for Asian Americans 
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(Table 6, Base model). Next we conducted these analyses with adjustment for a limited 
number of clinical characteristics and without consideration of reproductive/lifestyle 
prognostic factors (parity, alcohol consumption, smoking) and other variables 
(differentiation, nodal involvement, tumor size, chemotherapy, prior tumor, SES, marital 
status, and year of diagnosis) as was usually done in SEER-based studies (5, 6) (Table 6, 
Limited Model 1). Relative to non-Latina Whites, the overall and breast cancer-specific 
mortality HR for African Americans increased (1.25 and 1.31, respectively); the overall HR 
in Latinas increased somewhat (0.82) but the breast cancer-specific HR remained 
unchanged, whereas the overall and breast cancer specific HR in Asian Americans decreased 
somewhat (0.71 and 0.56, respectively). When we repeated these analyses without 
stratification by study (Table 6, Limited Model 2), relative to non-Latina Whites, the HRs 
for overall and breast cancer-specific mortality in African Americans increased further (1.46 
and 1.52, respectively), the HRs in Latinas approached unity (0.99 and 1.00, respectively), 
and the HRs in Asian Americans remained substantially lower than 1.0 (0.82 and 0.84, 
respectively).
Finally, we tested the Limited Model 2 using all 289,058 breast cancer patients in the CCR 
and found that the HRs for overall and breast cancer-specific mortality in Latinas were 
comparable to those in non-Latina Whites (1.01 and 1.01, respectively). In contrast, the HRs 
in African Americans were higher (1.36 and 1.42, respectively) and those in Asian 
Americans were lower (0.80 and 0.85, respectively) than the HRs in non-Latina Whites 
(Table 6, Limited model 2-CCR).
Discussion
Numerous observational studies have examined the role of diet, adiposity, physical activity, 
and other lifestyle factors in relation to the risk of breast cancer development. However, 
much less is known about the role of lifestyle factors and their interactions with contextual 
factors in relation to breast cancer prognosis, particularly in non-White populations. To our 
knowledge, the CBCSC is the largest study on breast cancer prognosis that includes lifestyle 
and contextual factors on a sizeable number of Latinas, African Americans, and Asian 
Americans, allowing for assessment of prognostic effects specific to each racial/ethnic group 
and comparison of the relative contribution of prognostic factors to disparities in survival 
across racial/ethnic groups.
The design and composition of the CBCSC study population differ from the study 
populations in three other large US studies on breast cancer prognosis (38-40). Our analysis 
primarily focuses on lifestyle factors before diagnosis of breast cancer, whereas the other 
three studies focused on lifestyle factors after breast cancer diagnosis. The Health, Eating, 
Activity, and Lifestyle (HEAL) Study (38) is a multicenter study of 1,183 breast cancer 
patients (615 Latinas from New Mexico, 202 Whites from Washington, 366 African 
Americans from LA County) diagnosed with in situ to stage IIIA breast cancer in the 1990s. 
Although the HEAL Study has been informative with regard to the relation between blood 
biomarkers and survival, this study is limited by the very small number of deaths to date (87 
total deaths, 42 deaths from breast cancer) (38). The After Breast Cancer Pooling Project 
(ABCPP) (39) was established in 2009 and includes over 18,000 breast cancer survivors 
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from four established studies to examine the role of physical activity, adiposity, supplement 
use, and quality of life in breast cancer prognosis. Although the number of non-Latina 
Whites in the ABCPP is almost twice as large as in our study, the numbers of African 
Americans (n=357), Latinas (n=387), and Asian Americans (n=292) are relatively small 
(39). The Pathways Study, a prospective cohort study of women diagnosed with breast 
cancer in Kaiser Permanente Northern California was initiated in 2006 (40). This study has 
now recruited nearly 4,500 women (8% African American, 12% Asian American, and 12% 
Latina) with an overarching goal to examine the associations of lifestyle and molecular 
factors with prognosis and survival (40). Thus, the CBCSC with its large numbers of non-
Whites and relatively long follow-up represents a unique resource to study prognosis-related 
factors within and across multiple racial/ethnic groups. A limitation of our study is the lack 
of information on lifestyle factors after diagnosis in five of our studies. However, results 
from LACE, which collected information after diagnosis, suggest generally similar levels of 
health-related behaviors before and after diagnosis, with the exception of weight gain during 
the first 1-3 years post-diagnosis (41, 42). In the Pathways Study, habits such as use of 
complementary and alternative therapy also did not show substantial changes from the 5 
years prior to diagnosis to after diagnosis (43). Similarly, in the HEAL Study, physical 
activity levels remained relatively stable up to 5 years postdiagnosis (44).
Various methodological issues were considered in the construction of the final baseline 
statistical model for our pooled analysis. A potential concern is the pooling of data from 
case-control and cohort studies. We conducted separate analysis by study design and did not 
find systematic differences across studies. This was tested formally in the context of our 
model as an interaction between race/ethnicity and study. The likelihood ratio tests for this 
effect on 11 degrees of freedom have p-values greater than 0.15 for both overall and breast 
cancer specific mortality. Our model included age at diagnosis as a continuous variable on 
both the natural scale and the log10 scale. Sensitivity analyses using categorized age 
confirmed that this approach captured the essential characteristics of the effect of age on 
overall and breast cancer-specific mortality. Missing or unknown values for relevant clinical 
characteristics and lifestyle prognostic factors were accounted for in the multivariate model 
by including a category for missing data. Although we considered using multiple imputation 
methods (45), we ultimately decided against this approach because the proportion of missing 
data is generally small in this cohort such that any bias in parameter estimates when 
compared with complete data is likely to be small. The multiple imputation approach also 
has some drawbacks as the appropriateness of assumptions required for its use may be 
impractical if imputation is needed for a large number of variables. We have accounted for 
competing risks in breast cancer-specific mortality analyses by censoring non-breast cancer 
causes of death. We evaluated the validity of this simpler approach by comparing it to a 
formal method for competing risks in Cox regression analysis proposed by Fine and 
colleagues (5, 46). This formal approach is computationally intensive compared to the 
simpler approach, but nevertheless yielded Cox regression parameter estimates that were 
essentially equivalent to those from the simpler approach (data not shown).
Our baseline overall and breast cancer-specific models were intended to capture racial/ethnic 
differences by adjusting for all relevant clinical characteristics and lifestyle prognostic 
factors, allowing us to evaluate whether the putative prognostic factors- contextual factors, 
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physical activity, body size, and co-morbidities- have additional effects on racial/ethnic 
differences in survival experience. Using this fully-adjusted baseline model, African 
Americans showed higher breast cancer-specific mortality than non-Latina Whites 
(HR=1.13), but their overall mortality was similar. In contrast, the overall and breast cancer-
specific mortality in Latinas and Asian Americans was considerably lower than in non-
Latina Whites. In SEER-based studies of overall mortality and breast cancer-specific 
mortality by race/ethnicity that adjusted for a limited number of clinical characteristics and 
were unable to adjust for individual lifestyle prognostic factors (5, 6, 37), the risks of overall 
and breast cancer-specific mortality were 1.5-1.8 fold higher among African Americans, and 
1.1-1.4 fold higher among Latinas, relative to non-Latina Whites, whereas the overall and 
breast cancer-specific mortality among Asian Americans was lower. To provide a 
comparison with SEER-based studies, we conducted analyses with CBCSC subjects that 
adjusted for a more limited number of clinical characteristics and did not adjust for 
individual lifestyle prognostic factors (Table 6, Limited Model 1). Results for CBCSC 
African Americans and Asian Americans were comparable to those reported in SEER-based 
studies showing respectively higher (HR= 1.2-1.3) and lower (HR=0.54-0.66) overall and 
breast cancer-specific mortality risks than was observed in CBCSC non-Latina Whites. 
However, contrary to the results from SEER-based studies, CBCSC Latinas did not have 
higher risk of overall and breast cancer-specific mortality than CBCSC non-Latina Whites. 
HRs in CBCSC and the CCR were comparable when we repeated the analyses using the 
Limited Model 2 and excluded ‘study’ as a stratification variable.
There are some possible explanations for these somewhat divergent results, particularly in 
CBCSC Latina breast cancer cases compared to those included in the SEER-based analyses. 
CBCSC cases represent women who were able and willing to complete detailed 
questionnaires or interviews and thus may not be representative of all breast cancer patients. 
In fact, we found that CBCSC participants had less advanced stage cancer (III/IV) than 
breast cancer patients in the CCR (Table 4) who, in turn, had somewhat better survival than 
women from a combination of SEER registries. Similarly, the prevalence of ER negative 
tumors was lowest among breast cancer patients in CBCSC, intermediate in the CCR, and 
highest in SEER. Interestingly, CBCSC non-Latina Whites and Latinas were more likely to 
live in high-SES neighborhoods than their counterparts in the CCR, but this was not 
observed for African American and Asian American women (Table 4). This difference in 
neighborhood SES may explain, in part, the better survival experience in CBCSC Latinas 
and this question will be investigated in future analyses as part of CBCSC Project 1 on 
contextual factors. Heterogeneity and regional differences within Latina and Asian 
American populations may also contribute to these differences in results. Latinas from 
Mexico, Puerto Rico, and South or Central America showed considerable differences in 
their breast cancer mortality (5, 6) such that the survival of Latinas in California, most 
(>80%) of whom are from Mexico (47), may not be representative of the survival of Latinas 
in the entire US. Similarly, our results for Asian Americans relate primarily to Chinese, 
Japanese, and Filipina women, who accounted for over 95% of the Asian women in CBCSC, 
but other Asian ethnic groups (e.g., Korean, Vietnamese) experience somewhat worse 
mortality than Chinese and Japanese women and also worse mortality than non-Latina 
Whites (5, 48).
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In summary, the CBCSC is well-positioned to study breast cancer outcomes across the 
major US racial/ethnic groups using the combined resources of six well-established studies 
covering multiethnic populations in California. We found racial/ethnic disparities in survival 
after breast cancer diagnosis that remained after adjustment for differences in several 
clinical, lifestyle, and neighborhood factors. However, there are some study limitations. 
While we successfully harmonized data on lifestyle prognostic factors, the questions were 
not identical across all the studies and some assumptions were made. Despite statistical 
adjustment for ‘study’, we cannot exclude the possibility of potential effect modification by 
study and race/ethnicity. One limitation of all studies of cause of death may be the variation 
in attributing deaths to a particular cause by the person completing the death certificate. If 
this were to vary by race/ethnicity, it could potentially bias the risk estimates but this would 
affect not only our results but those of all other studies. We were also limited by the fact that 
only information on first course of treatment is available from the CCR and uncontrolled 
confounding by treatment may exist although we have previously shown that registry data 
on treatment including chemotherapy and surgery are of high quality (49). There are also 
important study strengths, including a large number of deaths due to breast cancer in African 
American, Latina, and Asian American breast cancer patients, which allowed us to examine 
the separate and combined effects of various lifestyle prognostic factors and tumor 
characteristics on survival. In addition, differential reporting of clinical and follow-up data 
by race/ethnicity was minimized given that these data were uniformly obtained from the 
CCR. The establishment of this rich resource provides the potential for unique insights 
regarding the roles of socioeconomic, medical, biological, cultural, and other determinants 
of racial/ethnic differences in breast cancer survival and opportunities for future studies of 
racial/ethnic disparities in breast cancer outcomes.
Acknowledgments
We are grateful to all the study participants for their contributions in the six California-based studies. We thank 
Juan Yang and Rita Leung at CPIC and Chiu-Chen Tseng at USC for their analytic support. This work was 
supported by grants (16ZB-8001 (USC, Wu), 16ZB-8002 (CPIC, Gomez), 16ZB-8003 (COH, Bernstein), 
16ZB-8004 (KPNC, Kwan), 16ZB-8005 (USC, Monroe) from the California Breast Cancer Research Program. The 
Asian American Breast Cancer Study was supported by the California Breast Research Program (CBCRP) grants 
1RB-0287, 3PB-0120, and 5PB-0018. The San Francisco Bay Area Breast Cancer Study was supported by National 
Cancer Institute grants R01 CA63446 and R01 CA77305; by the U.S. Department of Defense (DOD) grant 
DAMD17-96-1-6071; and by the CBCRP grants 4JB-1106 and 7PB-0068. The Women's CARE Study was funded 
by the National Institute of Child Health and Human Development (NICHD), through a contract with USC (N01-
HD-3-3175), and the California Teachers Study was funded by the California Breast Cancer Act of 1993; National 
Cancer Institute grants (R01 CA77398 and K05 CA136967 to LB); and the California Breast Cancer Research Fund 
(contract 97-10500). The Multiethnic Cohort Study was supported by National Cancer Institute grants R01 
CA54281, R37CA54281, and UM1 CA164973. The Life After Cancer Epidemiology Study is supported by 
National Cancer Institute grant R01 CA129059. Clinical and tumor characteristics and mortality data were obtained 
from the California Cancer Registry (CCR), also part of the National Cancer Institute's Division of Cancer 
Prevention and Control Surveillance, Epidemiology, and End Results Program, under contract number 
N01CN25403. The collection of cancer incidence data used in this study was supported by the California 
Department of Health Services as part of the statewide cancer reporting program mandated by California Health 
and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results 
Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract 
HHSN26120100035C awarded to the University of Southern California, and contract HHSN26120100034C 
awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of 
Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The ideas and 
opinions expressed herein are those of the authors, and endorsement by the State of California, the California 
Department of Health Services, the National Cancer Institute, or the Centers for Disease Control and Prevention or 
their contractors and subcontractors is not intended nor should be inferred.
Wu et al. Page 12














1. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites 
after a cancer diagnosis. JAMA. 2002; 287:2106–13. [PubMed: 11966385] 
2. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer 
survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, 
and demographics? Cancer. 2008; 112:171–80. [PubMed: 18040998] 
3. Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in 
the United States. J Clin Oncol. 2005; 23:7836–41. [PubMed: 16258086] 
4. Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol. 2003; 4:251–4. 
[PubMed: 12681269] 
5. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race 
and ethnicity. Arch Intern Med. 2003; 163:49–56. [PubMed: 12523916] 
6. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/
ethnicity. Breast Cancer Res Treat. 2011; 127:729–38. [PubMed: 21076864] 
7. McKenzie F, Jeffreys M. Do lifestyle or social factors explain ethnic/racial inequalities in breast 
cancer survival? Epidemiol Rev. 2009; 31:52–66. [PubMed: 19675112] 
8. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: a critical review of the evidence. 
Breast Cancer Res Treat. 1990; 16:205–14. [PubMed: 2085672] 
9. Abrahamson PE, Gammon MD, Lund MJ, et al. General and abdominal obesity and survival among 
young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15:1871–7. [PubMed: 
17035393] 
10. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: 
systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123:627–35. [PubMed: 
20571870] 
11. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage 
breast cancer. J Clin Oncol. 2010; 29:25–31. [PubMed: 21115856] 
12. Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast 
cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012; 132:729–39. 
[PubMed: 22187127] 
13. Cleveland RJ, Eng SM, Abrahamson PE, et al. Weight gain prior to diagnosis and survival from 
breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16:1803–11. [PubMed: 17855698] 
14. Keegan TH, Milne RL, Andrulis IL, et al. Past recreational physical activity, body size, and all-
cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. 
Breast Cancer Res Treat. 2010; 123:531–42. [PubMed: 20140702] 
15. Sternfeld B, Weltzien E, Quesenberry CP Jr, et al. Physical activity and risk of recurrence and 
mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomarkers 
Prev. 2009; 18:87–95. [PubMed: 19124485] 
16. West-Wright CN, Henderson KD, Sullivan-Halley J, et al. Long-term and recent recreational 
physical activity and survival after breast cancer: the California Teachers Study. Cancer Epidemiol 
Biomarkers Prev. 2009; 18:2851–9. [PubMed: 19843680] 
17. Braithwaite D, Tammemagi CM, Moore DH, et al. Hypertension is an independent predictor of 
survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009; 
124:1213–9. [PubMed: 19058216] 
18. Tammemagi CM. Racial/ethnic disparities in breast and gynecologic cancer treatment and 
outcomes. Curr Opin Obstet Gynecol. 2007; 19:31–6. [PubMed: 17218849] 
19. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and 
comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001; 
285:885–92. [PubMed: 11180731] 
20. Sprague BL, Trentham-Dietz A, Gangnon RE, et al. Socioeconomic status and survival after an 
invasive breast cancer diagnosis. Cancer. 2011; 117:1542–51. [PubMed: 21425155] 
Wu et al. Page 13













21. Pike MC, Kolonel LN, Henderson BE, et al. Breast cancer in a multiethnic cohort in Hawaii and 
Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in 
whites. Cancer Epidemiol Biomarkers Prev. 2002; 11:795–800. [PubMed: 12223421] 
22. Berstad P, Coates RJ, Bernstein L, et al. A case-control study of body mass index and breast cancer 
risk in white and African-American women. Cancer Epidemiol Biomarkers Prev. 2010; 19:1532–
44. [PubMed: 20501755] 
23. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. Br J 
Cancer. 2012; 107:1608–17. [PubMed: 22996614] 
24. Keegan TH, Quach T, Shema S, Glaser SL, Gomez SL. The influence of nativity and 
neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic 
women. BMC Cancer. 2010; 10:603. [PubMed: 21050464] 
25. Lu Y, Ma H, Malone KE, et al. Obesity and survival among black women and white women 35 to 
64 years of age at diagnosis with invasive breast cancer. J Clin Oncol. 2011; 29:3358–65. 
[PubMed: 21788570] 
26. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and 
breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study. 
Breast Cancer Res Treat. 2011; 129:565–74. [PubMed: 21499688] 
27. Gomez SL, Glaser SL, McClure LA, et al. The California Neighborhoods Data System: a new 
resource for examining the impact of neighborhood characteristics on cancer incidence and 
outcomes in populations. Cancer Causes Control. 2011; 22:631–47. [PubMed: 21318584] 
28. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer 
incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12:703–11. 
[PubMed: 11562110] 
29. Phillips KA, Milne RL, West DW, et al. Prediagnosis reproductive factors and all-cause mortality 
for women with breast cancer in the breast cancer family registry. Cancer Epidemiol Biomarkers 
Prev. 2009; 18:1792–7. [PubMed: 19505912] 
30. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the 
incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008; 26:3310–
6. [PubMed: 18612147] 
31. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors 
to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev. 2002; 11:235–41. [PubMed: 
11895871] 
32. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive 
history and mortality after breast cancer diagnosis. Obstet Gynecol. 2004; 104:146–54. [PubMed: 
15229014] 
33. Alsaker MD, Opdahl S, Asvold BO, Romundstad PR, Vatten LJ. The association of reproductive 
factors and breastfeeding with long term survival from breast cancer. Breast Cancer Res Treat. 
2011; 130:175–82. [PubMed: 21553291] 
34. Vrieling A, Buck K, Heinz J, et al. Pre-diagnostic alcohol consumption and postmenopausal breast 
cancer survival: a prospective patient cohort study. Breast Cancer Res Treat. 2012; 136:195–207. 
[PubMed: 22961011] 
35. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: 
choice of the time-scale. Am J Epidemiol. 1997; 145:72–80. [PubMed: 8982025] 
36. Pencina MJ, Larson MG, D'Agostino RB. Choice of time scale and its effect on significance of 
predictors in longitudinal studies. Stat Med. 2007; 26:1343–59. [PubMed: 16955538] 
37. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and 
minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based 
study. Arch Intern Med. 2002; 162:1985–93. [PubMed: 12230422] 
38. Duggan C, Wang CY, Neuhouser ML, et al. Associations of insulin-like growth factor and insulin-
like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer. 
2013; 132:1191–200. [PubMed: 22847383] 
39. Nechuta SJ, Caan BJ, Chen WY, et al. The After Breast Cancer Pooling Project: rationale, 
methodology, and breast cancer survivor characteristics. Cancer Causes Control. 2011; 22:1319–
31. [PubMed: 21710192] 
Wu et al. Page 14













40. Kushi LH, Kwan ML, Lee MM, Ambrosone CB. Lifestyle factors and survival in women with 
breast cancer. J Nutr. 2007; 137:236S–42S. [PubMed: 17182833] 
41. Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML. Life After Cancer 
Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States). 
Cancer Causes Control. 2005; 16:545–56. [PubMed: 15986109] 
42. Caan BJ, Kwan ML, Hartzell G, et al. Pre-diagnosis body mass index, post-diagnosis weight 
change, and prognosis among women with early stage breast cancer. Cancer Causes Control. 2008; 
19:1319–28. [PubMed: 18752034] 
43. Greenlee H, Kwan ML, Ergas IJ, et al. Complementary and alternative therapy use before and after 
breast cancer diagnosis: the Pathways Study. Breast Cancer Res Treat. 2009; 117:653–65. 
[PubMed: 19184414] 
44. Mason C, Alfano CM, Smith AW, et al. Long-Term Physical Activity Trends in Breast Cancer 
Survivors. Cancer Epidemiol Biomarkers Prev. 2013; 22:1153–61. [PubMed: 23576689] 
45. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999; 8:3–15. [PubMed: 
10347857] 
46. Fine, JP.; Gray, RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk 
Journal of the. American Statistical Association: Taylor & Francis; 1999. p. 496-509.
47. Center, PH. Demographic profile of Hispanics in California. 2009. http://pewhispanic.org/states/?
stateid=CA
48. Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan TH, Glaser SL. Disparities in breast cancer 
survival among Asian women by ethnicity and immigrant status: a population-based study. Am J 
Public Health. 2010; 100:861–9. [PubMed: 20299648] 
49. Kurian AW, Lichtensztajn DY, Keegan TH, et al. Patterns and predictors of breast cancer 
chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 
2012; 137:247–60. [PubMed: 23139057] 
50. Wu AH, Yu MC, Tseng CC, Pike MC. Body size, hormone therapy and risk of breast cancer in 
Asian-American women. Int J Cancer. 2007; 120:844–52. [PubMed: 17131315] 
51. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast 
cancer. N Engl J Med. 2002; 346:2025–32. [PubMed: 12087137] 
52. John EM, Phipps AI, Davis A, Koo J. Migration history, acculturation, and breast cancer risk in 
Hispanic women. Cancer Epidemiol Biomarkers Prev. 2005; 14:2905–13. [PubMed: 16365008] 
53. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California 
teachers: results from the California Teachers Study (United States). Cancer Causes Control. 2002; 
13:625–35. [PubMed: 12296510] 
54. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: 
baseline characteristics. Am J Epidemiol. 2000; 151:346–57. [PubMed: 10695593] 
Wu et al. Page 15













Figure 1. Eligibility Flow and Organization Structure of the California Breast Cancer 
Survivorship Consortium (CBCSC)
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Table 5
Hazard Ratios (HR) and Coefficient of Variation (CV)a for Final Models for All-Cause 
and Breast Cancer-Specific Mortality Models in the CBCSC
Overall Mortality Breast Cancer-Specific Mortality
Variable
Attained Age




40 0.67 0.19-2.31 0.47 0.08-2.61
50 0.92 0.52-1.63 0.66 0.29-1.48
60 1.00 1.00
70 0.92 0.54-1.56 1.62 0.76-2.34
80 0.75 0.27-2.12 2.76 0.62-12.2
Stage (AJCC)c
I 1.00 1.00
II 1.22 1.09-1.37 1.76 1.46-2.12
III 1.97 1.62-2.40 3.14 2.41-4.09
IV 4.79 3.82-6.00 7.98 5.94-10.7
Unknown 0.97 0.77-1.23 1.26 0.90-1.78
Grade
I 1.00 1.00
II 1.16 1.03-1.31 1.61 1.29-2.02
III/IV 1.53 1.35-1.73 2.59 2.07-3.25
Unknown 1.14 0.99-1.33 1.60 1.23-2.09
Nodal involvement
No 1.00 1.00
Yes 1.55 1.39-1.73 1.96 1.69-2.28
Unknown 1.80 1.53-2.12 2.30 1.81-2.91
Tumor size (cm)
<1 1.00 1.00
1-<5 1.24 1.09-1.41 1.88 1.46-2.43
≥5 1.41 1.16-1.71 2.22 1.64-3.01
Unknown 1.69 1.37-2.09 2.65 1.92-3.64
Surgery type
No surgery 1.00 1.00
Mastectomy 0.58 0.48-0.71 0.50 0.39-0.64
Lumpectomy 0.50 0.41-0.61 0.41 0.32-0.53
Other 0.66 0.29-1.53 0.53 0.17-1.73
ER/PR c status
ER+/PR+ 1.00 1.00
ER+/PR- 1.22 1.08-1.37 1.30 1.10-1.54
ER-/PR+ 0.99 0.76-1.28 1.08 0.78-1.49
ER-/PR- 1.35 1.21-1.50 1.46 1.28-1.67
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Overall Mortality Breast Cancer-Specific Mortality
Variable
Attained Age
HR a 95% CI
Attained Age
HRa 95% CI
ER/PR Unknown 1.10 0.99-1.22 1.21 1.04-1.40
Chemotherapy
No 1.00 1.00
Yes 1.20 1.09-1.32 1.27 1.11-1.46






Yes 1.45 1.28-1.64 1.23 1.01-1.50
Neighborhood SES c
Lowest 1.00 1.00
Lower-middle 1.01 0.89-1.15 0.96 0.80-1.15
Middle SES 0.92 0.81-1.05 0.85 0.71-1.02
Higher-middle 0.78 0.68-0.90 0.78 0.65-0.94
Highest 0.84 0.72-0.97 0.77 0.64-0.94
Unknown 0.85 0.66-1.10 0.82 0.57-1.18
Race/ethnicity
Non-Latina White 1.00 1.00
African American 1.02 0.91-1.15 1.13 0.97-1.33
Latina 0.75 0.65-0.87 0.84 0.70-1.00
Asian American 0.76 0.57-1.01 0.60 0.37-0.97
Other 0.96 0.62-1.47 1.00 0.51-1.95
Marital status
Single, never married 1.00 1.00
Married 0.94 0.83-1.05 1.05 0.90-1.22
Separated/Divorced 1.20 1.04-1.37 1.25 1.04-1.51
Widowed 1.11 0.96-1.27 1.25 1.02-1.53
Unknown 0.89 0.68-1.16 0.86 0.58-1.27
Educational level
<high school 1.00 NId
high school 0.78 0.68-0.90
some college 0.81 (0.07) 0.71-0.93
college graduate or more 0.66 (0.08) 0.57-0.77
Unknown 0.71 (0.36) 0.39-1.29
Age at first birth
 < 20 1.00 NId
 20-24 0.96 0.86-1.07
 25-29 0.93 0.81-1.06
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Overall Mortality Breast Cancer-Specific Mortality
Variable
Attained Age
HR a 95% CI
Attained Age
HRa 95% CI
 30-34 1.05 0.90-1.24
 ≥35 0.95 0.76-1.18
 Nulliparous 1.11 0.97-1.27
 Missing 1.22 0.93-1.61
Smoking status
 Never 1.00 1.00
 Past ≤1 pack/day 1.11 1.00-1.22 1.15 1.00-1.31
 Past >1 pack/day 1.37 1.15-1.62 1.18 0.91-1.53
 Current ≤1 pack/day 1.46 1.28-1.68 1.22 1.01-1.47
 Current >1 pack/day 2.07 1.60-2.69 1.63 1.11-2.38
 Unknown 1.39 1.16-1.65 1.61 1.25-2.07
Alcohol consumption
Non-drinker 1.00 NId NId
≤ 2 drinks/week 0.84 0.76-0.93
>2 drinks/week 0.88 0.81-0.97
Unknown 1.05 0.88-1.28
US born





1996-1998 0.97 0.87-1.09 0.92 0.79-1.07
1999-2001 0.85 0.74-0.97 0.80 0.66-0.97
2001-2004 0.89 0.75-1.05 0.82 0.66-1.07
2005-2007 0.84 0.66-1.06 0.81 0.60-1.11
Residency region
Region 1 1.00 1.00
CSP of Orange County 0.71 0.53-0.94 0.63 0.41-0.98
Central California 1.08 0.83-1.40 0.97 0.66-1.45
CSP/Sutter Cancer Center 0.86 0.69-1.08 0.75 0.54-1.05
Tri-Counties 0.79 0.57-1.10 0.79 0.48-1.30
Desert Sierra CSP 0.94 0.72-1.24 0.87 0.58-1.29
Cancer Registry of N 
California
1.05 0.82-1.36 0.96 0.65-1.43
San Diego/Imperial 1.15 0.89-1.49 0.97 0.65-1.44
Northern California 
Cancer Center
1.09 0.94-1.27 1.04 0.84-1.27
CSP of Los Angeles 1.09 0.89-1.35 1.05 0.77-1.44
a
95% CI
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b
HR estimates for specific ages at diagnosis are computed from the Cox model regression parameters of continue Age and log (Age).
c
American Joint Committee on Cancer (AJCC), estrogen receptor(ER)/progesterone receptor (PR), socioeconomic status (SES)
d
HR estimates are not shown for variables that were not included (NI) in the final model.
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